论文部分内容阅读
目的：观察血管内皮生长因子（ Ｖ Ｅ Ｇ Ｆ） 对喉癌细胞增殖动力学的影响。方法：首先建立荷瘤（ Ｈ Ｅ Ｐ２ 喉癌细胞） 裸鼠动物模型，将抗 Ｖ Ｅ Ｇ Ｆ 抗体及抗 Ｖ Ｅ Ｇ Ｆ 受体ｆｌｔ 抗体分别注射荷瘤鼠体内，通过活体标记 Ｂｒｄ Ｕ 的方法，观察抗 Ｖ Ｅ Ｇ Ｆ 抗体及抗ｆｌｔ 抗体对喉癌 Ｈ Ｅ Ｐ２ 细胞增殖的影响。结果：与对照组相比较，抗 Ｖ Ｅ Ｇ Ｆ 抗体治疗组 Ｈ Ｅ Ｐ２细胞 Ｂｒｄ Ｕ 标记阳性率显著降低（ Ｐ＜ ０ ．０５） ；抗ｆｌｔ 抗体治疗组 Ｂｒｄ Ｕ 标记阳性率亦显著小于对照组（ Ｐ＜ ０．０５） ；而抗 Ｖ Ｅ Ｇ Ｆ 抗体治疗组与抗ｆｌｔ 抗体治疗组 Ｂｒｄ Ｕ 标记率无显著性差异（ Ｐ ＞ ０．０５） 。结论：中和 Ｖ Ｅ Ｇ Ｆ 抗体的作用及封闭 Ｖ Ｅ Ｇ Ｆ 结合位点均可抑制喉癌细胞的增殖，提示 Ｖ Ｅ Ｇ Ｆ 与喉癌细胞生长有着密切的关系。
Objective: To observe the effect of vascular endothelial growth factor (V E G F) on the proliferation kinetics of laryngeal cancer cells. METHODS: First, animal model of tumor-bearing (H E P 2 larynx cancer cell) nude mice was established. Anti-V E G F antibody and anti-V E G F receptor flt antibody were respectively injected into tumor-bearing mice to mark Brd U in vivo. The method was used to observe the effect of anti-V E G F antibody and anti-flt antibody on proliferation of laryngeal cancer HE P 2 cells. RESULTS: Compared with the control group, the positive rate of BrdU labeling in the H E P 2 cells was significantly lower in the anti-V E G F antibody-treated group (P < 0.05). The positive rate of Brd U-labeling was also significantly lower in the anti-Flt antibody-treated group. There was no significant difference in the Brd U labeling rate between the anti-V E G F antibody-treated group and the anti-flt antibody-treated group (P > 0.05). Conclusion: The effect of neutralizing V E G F antibody and blocking V E G F binding site can inhibit the proliferation of laryngeal cancer cells, suggesting that V E G F has a close relationship with the growth of laryngeal cancer cells.